Cambridge Healthtech Institute’s 6th Annual

Small Molecules for Cancer Targets

Discovering Targeted, Oral-Based Oncology Therapeutics

October 1-2, 2024


Join CHI’s Small Molecules for Cancer Targets conference to hear progress in potential new small molecule-based cancer therapeutics against novel drug targets. Small molecules have the advantage of being able to modulate intracellular proteins, which biologics are too large to reach, thereby widening the cancer-associated pathways that can be modulated. Plus, small molecules have the chemical properties to be made orally bioavailable, offering more convenience for patients and logistics. Challenges remain, however. For example, many intracellular cancer culprits are part of protein complexes for which traditional enzyme inhibitor-based drug discovery approaches don’t apply. Molecular glue and degrader approaches are showing potential for those reasons, but the technologies are in their early days. Share insights, learn from colleagues and stay abreast of the most promising small molecule translational oncology research.


Who should attend: Scientists, Directors of Research, Vice Presidents, CSOs, Professors, Post-Doctoral Fellows, Graduate Students in departments such as: Discovery Chemistry, Discovery Biology, Discovery Oncology, Immuno-Oncology, Oncology Discovery, Immunology Discovery, Oncology Pharmacology, Discovery Pharmacology


Coverage will include, but is not limited to:


  • Immuno-oncology targeted small molecule drug leads (e.g.; macrophage and T cell checkpoint inhibitors)
  • Updates on targeting the innate immune system and pattern recognition receptors (inflammasome, TLRs, NLRP3, STING and more)
  • Modulating the tumor microenvironment with small molecules
  • Membrane protein small molecule cancer targets stories (GPCRs, transporters and more)
  • Targeted-protein degradation approaches
  • Synthetic lethal strategies
  • Medicinal chemistry advances such as covalent-targeting and more
  • Progess targeting small molecule intracellular cancer targets (Ras/MAPK pathway, transcription factors, kinases)


The deadline for priority consideration is March 8, 2024.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


Opportunities for Participation:



For more details on the conference, please contact:

Anjani Shah, PhD

Senior Conference Director

Cambridge Healthtech Institute

Phone: (+1) 781-247-6252



For sponsorship information, please contact:

Kristin Skahan

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-972-5431